Welcome to our dedicated page for Cellectis news (Ticker: CLLS), a resource for investors and traders seeking the latest updates and insights on Cellectis stock.
Cellectis S.A. (NASDAQ: CLLS) is a clinical-stage biopharmaceutical leader developing groundbreaking allogeneic CAR-T therapies through precision gene-editing technologies. This page provides investors and industry professionals with essential updates on the company’s clinical trials, regulatory milestones, and strategic developments.
Access real-time announcements including FDA submissions, partnership agreements, and research breakthroughs. Our curated collection features press releases on TALEN®-engineered therapies, hematopoietic stem cell advancements, and financial results – all critical for evaluating this innovator in off-the-shelf cancer treatments.
Key updates cover three focus areas: clinical trial phases for UCART candidates, intellectual property developments, and collaborative research initiatives. Bookmark this page to monitor progress in scalable cancer immunotherapies and maintain informed perspectives on Cellectis’ position within the competitive gene-editing landscape.
Cellectis reported its Q3 2022 results, highlighting a cash position of $103 million as of September 30, 2022. Revenues fell to $9 million, down from $53 million in the same period last year, primarily due to decreased milestone payments. R&D expenses were $85 million, reflecting notable cost management. The net loss attributable to shareholders decreased to $79 million or $1.74 per share, compared to $89 million in the prior year. Additionally, several clinical trials progressed, including UCART123's upcoming oral presentation at the ASH 2022 Annual Meeting.
Cellectis has announced two abstracts accepted for presentation at the 64th ASH Annual Meeting from December 10-13, 2022. The AMELI-01 study evaluating UCART123 in patients with relapsed/refractory acute myeloid leukemia (r/r AML) will showcase preliminary data, highlighting improved activity with alemtuzumab. Additionally, a poster on UCARTCS1 will present preclinical data demonstrating anti-tumor activity in multiple myeloma. Cellectis aims to address unmet medical needs using its gene-editing platform to develop innovative therapies.
Cellectis, a clinical-stage biotechnology company, is set to announce its Q3 2022 financial results on November 3, 2022, after the US market closes. This will be followed by a conference call on November 4, 2022, at 8:00 AM EDT to discuss the results and provide a business update. Cellectis focuses on developing innovative gene-editing therapies using TALEN® technology and is pioneering off-the-shelf CAR-T immunotherapies. The company is listed on Nasdaq under the symbol CLLS.
Cellectis, a clinical-stage biotechnology company, announced pre-clinical data on TALEN®-edited CAR T-cells aimed at solid tumors, to be presented at the Society for Immunotherapy of Cancer's 37th Annual Meeting from November 8-12, 2022. Key presentations include:
- Poster on MUC1-targeting CAR T-cells for triple-negative breast cancer (Poster Number: 217).
- Poster on engineering strategies to enhance CAR T-cell efficacy (Poster Number: 325).
Cellectis utilizes its TALEN® technology to develop innovative therapies for unmet medical needs in oncology.
Cellectis, a clinical-stage biotechnology company focused on gene-editing technology, has appointed Dr. Mark Frattini as Chief Medical Officer, effective immediately. Dr. Frattini has over 20 years of experience in hematological malignancies and was previously Senior Vice President of Clinical Sciences at Cellectis. His role will encompass overseeing clinical research and development for the company's UCART clinical trial programs. Dr. Frattini's extensive expertise aims to advance the company’s CAR T-cell therapies, addressing critical patient needs in blood cancer treatment.
Cellectis, a clinical-stage biotechnology company, is advancing its gene-editing technology, TALEN®, to develop innovative cell therapies for cancer treatment. As of August 31, 2022, the company reported a total of 45,550,810 shares in capital and 51,615,672 voting rights. With over 22 years of expertise in gene editing, Cellectis focuses on off-the-shelf CAR-T therapies aimed at various blood cancers, including AML and B-ALL. The company is listed on both the Nasdaq Global Market (ticker: CLLS) and Euronext Growth (ticker: ALCLS).
Cellectis, a clinical-stage biotechnology company focused on gene editing, has announced its participation in four upcoming investor conferences. These events include Citi's 17th Annual Biopharma Conference on September 7, 2022, and the Wells Fargo 2022 Healthcare Conference from September 7-9, followed by presentations at the Baird Global Healthcare Conference on September 13 and the Jefferies Cell and Genetic Medicine Summit on September 29. Cellectis is dedicated to developing innovative therapies for cancer and genetic diseases using its proprietary TALEN® technology and aims to provide treatment options for various cancers.
Cellectis announced its share and voting rights update as of July 31, 2022. The total number of ordinary shares in circulation stands at 45,510,810, with total voting rights reaching 51,875,672. This report is part of compliance with the French financial markets authority regulations.
As a leading clinical-stage biotechnology company, Cellectis is focused on developing innovative cell and gene therapies utilizing its gene-editing technology, TALEN®, and aims to address unmet medical needs in oncology.
Cellectis has received FDA clearance for its IND application for UCART20x22, targeting Non-Hodgkin Lymphoma. With a cash position of $135 million as of June 30, 2022, the company is well-positioned for upcoming clinical trials. Cellectis is progressing in enrolling patients in three Phase 1 trials and plans to initiate the NatHaLi-01 clinical trial this year. However, the company reported a significant drop in revenue, from $43 million in the first half of 2021 to $7 million in 2022, primarily due to decreased collaboration income.
